Review Opinions of the Remuneration and Assessment Committee on the Company's 2026 Restricted Stock Incentive Plan
Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "the Company") Remuneration and Assessment Committee has conducted a review of the "Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. 2026 Restricted Stock Incentive Plan (Draft)" (hereinafter referred to as "the Incentive Plan") and related matters in accordance with the Company Law of the People's Republic of China (hereinafter referred to as "the Company Law"), the Securities Law of the People's Republic of China (hereinafter referred to as "the Securities Law"), the Management Measures for Equity Incentives of Listed Companies (hereinafter referred to as "the Management Measures"), and other relevant laws, regulations, rules, and normative documents, as well as the Articles of Association of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "the Articles of Association"). The review opinions are as follows: